NSW Health wants to amend its defence to an underpayments class action on behalf of 24,000 junior doctors, bringing claims that the lead applicant is barred from seeking compensation for group members under industrial relations law.
Pharmaceutical giants Merck Sharpe & Dohme and Pfizer have resolved a long-running intellectual property dispute over a 2015 patent owned by Pfizer for a pneumococcal vaccine.
A judge has set aside a subpoena that allegedly sought to āembarrass the New South Wales governmentā, in lawsuits contesting compulsory COVID-19 vaccination orders made by state health minister Brad Hazzard.
An Australian generic drug manufacturer has struck back at patent lawsuit by Swiss pharmaceutical company Biogen, alleging a patent for MS drug Tecfidera is invalid and a that a patent term extension for the drugĀ was wrongly granted.
Avant Insurance has lost a bid to pause an order that it pay $371,000 in the legal costs of a surgeon facing a class action by breast implant patients of defunct clinic the Cosmetic Institute while the insurer’s appeal is pending.
Hundreds of women who suffered āchaos and devastationā at the hands of former surgeon Emil Gayed will be entitled to compensation after class action law firm Slater & Gordon negotiated with the state government to secure a redress scheme.
Merck Sharp & Dohme is seeking to overturn a judgment refusing an extension of a patent covering its Januvia and Janumet diabetes drugs that would have seen the US drug maker of retaining a monopoly over the multibillion dollar medicines beyond July 2022.
Botox maker Allergan has successfully challenged a Federal Court judgment dismissing its trade mark lawsuit against an Australian company selling topical creams as an alternative to Botox injections.
Avant Insurance has launched an appeal of a Federal Court judgment ordering it to cover the defence costs of a surgeon facing a class action by breast implant patients of defunct clinic the Cosmetic Institute.
Tens of thousands of hospital patients were put at risk when Medtronic unlawfully supplied a bone grafting kit to hospitals that was not registered on the Australian Register of Therapeutic Goods, according to new regulatory proceedings.